来氟米特治疗“类风湿狼疮综合征”：临床及能量多普勒超声监测反应。一项纵向的初步研究。
Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study.
机构信息
Chair of Rheumatology and Rheumatology Unit, University Clinic and AOU of Cagliari, Cagliari, Italy.
出版信息
Lupus. 2013 May;22(6):624-8. doi: 10.1177/0961203313482741. Epub 2013 Apr 4.
OBJECTIVE
To evaluate the safety and efficacy of rituximab in patients suffering from rhupus unresponsive to therapy with non-biological disease-modifying anti-rheumatic drugs (DMARDs).
METHODS
Six patients fulfilling criteria for both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and with a DAS28 score >5.1 were enrolled to receive two fortnightly 1000 mg rituximab doses at baseline and after 28 weeks. All patients underwent clinical, laboratory, and power- Doppler (PD) ultrasonographic (US) assessment at baseline and after 14, 28 and 56 weeks.
RESULTS
A sustained improvement in DAS28, SLEDAI, HAQ, laboratory markers and ultrasound indices together with a significant reduction in the daily dose of prednisone were observed throughout follow-up.
CONCLUSION
Rituximab may be a safe and effective therapeutic option in refractory rhupus patients.
目的
评估利妥昔单抗治疗对非生物性疾病修饰抗风湿药物（DMARDs）治疗反应不佳的红斑狼疮患者的安全性和疗效。
方法
纳入符合类风湿关节炎（RA）和系统性红斑狼疮（SLE）标准且 DAS28 评分>5.1 的 6 例患者，在基线和 28 周时分别接受两次每两周 1000mg 利妥昔单抗剂量治疗。所有患者在基线和 14、28 和 56 周时进行临床、实验室和功率多普勒（PD）超声（US）评估。
结果
在整个随访过程中，DAS28、SLEDAI、HAQ、实验室标志物和超声指数持续改善，泼尼松的日剂量显著降低。
结论
利妥昔单抗可能是治疗难治性红斑狼疮患者的安全有效治疗选择。
Zotero 插件